OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Simeone on the Importance of Germline Testing in Pancreatic Cancer

June 5th 2020

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Dr. Kelly on the Rationale for Combining Radium-223 and Niraparib in mCRPC

June 5th 2020

William Kevin Kelly, DO, discusses the rationale for a phase 1b dose-finding study evaluating the combination radium-223 dichloride and niraparib in patients with metastatic castration-resistant prostate cancer.

Dr. Lee on Combining TKIs With Immunotherapy in mRCC

June 4th 2020

Chung-Han Lee, MD, PhD, discusses the potential for combining TKIs with immunotherapy in patients with metastatic renal cell carcinoma who have progressed on prior checkpoint inhibitors.

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

June 4th 2020

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

Dr. Klein on Predicting Tumor Aggressiveness With Oncotype DX Test in Prostate Cancer

June 4th 2020

Eric A. Klein, MD, discusses the Oncotype DX test and how it is utilized to predict tumor aggressiveness in patients with prostate cancer.

Dr. Chi on the Prostate Cancer Biomarker Enrichment and Treatment Selection Study

June 4th 2020

Kim Chi, MD, discusses prostate cancer biomarker enrichment and treatment selection study.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 4th 2020

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

Dr. Armaghany on the Utility of ctDNA in CRC

June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Favret on Extending Survival and Improving Outcomes in Breast Cancer

June 4th 2020

Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

June 4th 2020

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

June 4th 2020

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

Dr. Gwin on the Safety of α-TEA Plus Trastuzumab in Recurrent HER2+ Breast Cancer

June 3rd 2020

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

Dr. Rotow on Results of a Phase 1/2 Trial With Osimertinib/Gefitinib in EGFR-Mutant NSCLC

June 3rd 2020

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Dr. Lonial on the Importance of Early Intervention in High-Risk Smoldering Myeloma

June 3rd 2020

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Dr. Cortes on Future Directions in MPNs

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

June 3rd 2020

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. McKay on Adapting Treatment for Patients With Cancer in COVID-19 Era

June 3rd 2020

Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. DiNardo on the Role of Venetoclax in AML

June 3rd 2020

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

NEXT PAGE
PREVIOUS PAGE